LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Strona główna・Stock List・Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc

Closed

SectorHealthcare

235.49 1.33

Buy Sell

Overview

Share price change

24h

Current

Min

229.94

Max

240.55

Key metrics
By Trading Economics
Income	-58M -13M
Sales	-7.9M 52M
P/E Sector Avg	29.958 49.888
EPS	-0.67
Profit margin	-25.801
Employees	47
EBITDA	-49M 17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+15.53% upside

Dividends
By Dow Jones
Next Earnings	6 sie 2026

Market Stats
By TradingEconomics
Market Cap	1.8B 4.6B
Previous open	234.16
Previous close	235.49

News Sentiment

By Acuity

50%

155 / 344 Ranking in Healthcare

Ligand Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 cze 2026, 21:51 UTC

Major Market Movers

Merlin Shares Rally After Defense Department's Design Review Wraps

4 cze 2026, 23:46 UTC

Market Talk

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 cze 2026, 23:44 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 cze 2026, 23:42 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 cze 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

Energy Resources of Australia to Enter Trading Halt

4 cze 2026, 23:34 UTC

Market Talk

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 cze 2026, 23:31 UTC

Market Talk

Global Equities Roundup: Market Talk

4 cze 2026, 23:08 UTC

Market Talk

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 cze 2026, 22:41 UTC

Market Talk

Australia Shares Set to Rise at the Open -- Market Talk

4 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 20:44 UTC

Acquisitions, Mergers, Takeovers

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 cze 2026, 20:16 UTC

Market Talk

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 cze 2026, 20:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 cze 2026, 19:46 UTC

Market Talk

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 cze 2026, 19:38 UTC

Market Talk

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 cze 2026, 19:30 UTC

Market Talk

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 cze 2026, 18:47 UTC

Acquisitions, Mergers, Takeovers

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 cze 2026, 18:38 UTC

Earnings

Money Quote: Tech Weakness in Context -- WSJ

4 cze 2026, 18:24 UTC

Earnings

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 17:09 UTC

Market Talk

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 cze 2026, 16:58 UTC

Earnings

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 cze 2026, 16:46 UTC

Market Talk

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 cze 2026, 16:38 UTC

Earnings

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

4 cze 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

4 cze 2026, 16:13 UTC

Market Talk

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 cze 2026, 16:11 UTC

Market Talk

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 cze 2026, 15:56 UTC

Market Talk

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Peer Comparison

Price change

Ligand Pharmaceuticals Inc Forecast

Price Target

By TipRanks

15.53% upside

12 Months Forecast

Average 270.8 USD 15.53%

High 289 USD

Low 255 USD

Based on 6 Wall Street analysts offering 12 month price targets forLigand Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Ligand Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

155 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.